Myasthenia gravis (MG) is a chronic, autoimmune neuromuscular disorder that disrupts the normal communication between nerves and muscles, leading to muscle weakness that worsens with activity and improves with rest. In individuals with MG, the immune system mistakenly produces antibodies that interfere with receptors at the neuromuscular junction — the critical connection point where nerve signals trigger muscle contraction. As a result, muscles may not receive consistent signals to move properly, causing symptoms that can fluctuate throughout the day and vary widely from person to person. Commonly affected muscle groups include those that control eye and eyelid movement, facial expression, chewing, swallowing, speaking, breathing, and limb function, making even routine daily activities challenging.

Myasthenia gravis can occur at any age and affects both men and women, with onset patterns that differ across populations. Some individuals experience mild symptoms limited to the eyes, while others develop generalized disease that impacts multiple muscle groups and significantly affects quality of life.  Clinical trials play a critical role in advancing care for people living with myasthenia gravis. These research studies help evaluate new treatment approaches designed to address the underlying mechanisms of the disease. Participation in clinical trials not only contributes to the development of future treatment options but may also provide eligible patients with access to cutting-edge therapies and comprehensive monitoring by experienced specialists.

At the Neurology Rare Disease Center, we are committed to supporting the myasthenia gravis community through active participation in clinical research and patient-centered care. Our team works closely with patients and families to help them understand available clinical trials, determine eligibility, and navigate each step of the research process with confidence and clarity. We invite you to learn more about the myasthenia gravis clinical trials currently available at our center and explore how participation may play a meaningful role in advancing treatment options — for yourself and for others living with MG.